37 results
PRE 14A
LRMR
Larimar Therapeutics Inc
12 Apr 24
Preliminary proxy
6:06am
. Shankar served as Vice President and Global Head, Biologics Development Sciences at Janssen Research & Development, Inc. (“Janssen R&D … ”), a pharmaceutical company of Johnson & Johnson, Inc. (“Johnson & Johnson”) from April 2018 to April 2022, where he led a global, 175-person R&D department
8-K
EX-99.2
LRMR
Larimar Therapeutics Inc
10 Nov 22
Larimar Therapeutics Reports Third Quarter 2022 Operating and Financial Results
7:01am
, Discovery & Non-clinical R&D Noreen Scherer VP, Clinical Operations Michael Celano Chief Financial Officer Keith E. Lynch, Jr. VP, Manufacturing
8-K
EX-99.1
klkwajiivt9g8y
20 Oct 22
October 2022 Larimar Therapeutics Corporate Presentation
8:11am
8-K
EX-99.2
qgn ofrnrvabtee
14 Sep 22
Other Events
7:05am
8-K
EX-99.2
9vsc37foep41ciptr5
11 Aug 22
Larimar plans to submit a complete response to CTI-1601’s clinical hold in the third quarter of 2022
4:13pm
8-K
EX-99.2
6ly iqs6qtvbwa
12 May 22
Larimar Therapeutics Reports First Quarter 2022 Operating and Financial Results
7:12am
8-K
EX-99.2
wjazzbm7yoniaw7 k47
25 Mar 22
Larimar Therapeutics Reports Fourth Quarter and Full Year 2021 Operating and Financial Results
7:11am
8-K
EX-99.1
ro7n33lmhj 7g098ax2
28 Feb 22
Results of Operations and Financial Condition
8:16am
8-K
EX-99.2
za2o8741 0h
12 Nov 21
Larimar Therapeutics Reports Third Quarter 2021 Operating and Financial Results
7:21am
8-K
EX-99.2
y9e66c
12 Aug 21
Larimar Therapeutics Reports Second Quarter 2021 Operating and Financial Results
10:29am
8-K
EX-99.1
7jykdkh
1 Jul 21
Other Events
6:11am
8-K
EX-99.1
34hursq0
14 Jun 21
Other Events
5:21pm
8-K
EX-99.1
fzbjggd
18 May 21
Other Events
3:09pm
8-K
EX-99.1
juaasfk31oqz8
8 Dec 20
Regulation FD Disclosure
7:40am
8-K
EX-99.2
3x5emz
10 Nov 20
Larimar Therapeutics Reports Third Quarter 2020 Operating and Financial Results
4:23pm